Krsnaa Diagnostics Ltd (KRSNAA) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Krsnaa Diagnostics highlighted its unique position in the Indian healthcare market, emphasizing its focus on serving underserved populations in Tier 2 and Tier 3 cities through a public-private partnership (PPP) model.
- The company reported a 16% revenue growth in FY25, reaching INR 7,172 million, driven by increased patient volumes and pricing efficiency.
- EBITDA increased by 34% to INR 1,958 million, with margins expanding by 370 basis points to 27%.
- Krsnaa Diagnostics served over 19 million patients and conducted over 61 million tests in FY25.
- The company's retail strategy gained momentum, expanding its presence 4x across Maharashtra, Punjab, Assam, and Orissa.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.